Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Association between p16 Promoter Methylation and Thyroid Cancer Risk: A Meta-analysis

  • Wu, Wei (Laboratory of Molecular Genetics of Aging & Tumor, Faculty of Medicing, Kunming University of Science and Technology) ;
  • Yang, Sheng-Fu (Department of Pharmacy, The First People's Hospital of Yunnan Province) ;
  • Liu, Fei-Fei (Laboratory of Molecular Genetics of Aging & Tumor, Faculty of Medicing, Kunming University of Science and Technology) ;
  • Zhang, Ji-Hong (Laboratory of Molecular Genetics of Aging & Tumor, Faculty of Medicing, Kunming University of Science and Technology)
  • Published : 2015.11.04
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The aim of the meta-analysis was to derive a more precise assessment of the association between p16 promoter methylation and thyroid cancer risk. Materials and Methods: The PubMed, Web of Science databases and Chinese CNKI were searched for relevant articles. Ultimately, seventeen case-control studies were included with a total of 804 thyroid cancer cases and 487 controls analysis by R Software (R version 3.1.2) including meta. Crude odds ratios with 95% confidence intervals were calculated using the random-effects model which were used to assess the strength of relationship between p16 methylation and lung carcinogenesis. Funnel plots were carried out to evaluate publication bias. Results: The meta-analysis results showed that the frequency of p16 promoter methylation in cancer tissue/blood was significantly higher than that normal tissue/blood (OR=5.46, 95%CI 3.12-9.55, P<0.0001) by random effects model with small heterogeneity. Conclusions: Thus, p16 promoter methylation may be associated with thyroid cancer risk.

Keywords

References

  1. Baylin SB (2005). DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol, 2, -11.
  2. Boltze C, Zack S, Quednow C, et al (2003). Hypermethylation of the CDKN2/p16INK4A promotor in thyroid carcinogenesis. Pathol Res Pract, 199, 399-404. https://doi.org/10.1078/0344-0338-00436
  3. Brait M, Loyo M, Rosenbaum E, et al (2012). Correlation between BRAF mutation and promoter methylation of TIMP3, RARbeta2 and RASSF1A in thyroid cancer. Epigenetics, 7, 710-9. https://doi.org/10.4161/epi.20524
  4. Budak A, Gulhan I, Aldemir OS, et al (2013). Lack of influence of pregnancy on the prognosis of survivors of thyroid cancer. Asian Pac J Cancer Prev, 14, 6941-3. https://doi.org/10.7314/APJCP.2013.14.11.6941
  5. Dai YL, Cai DH, Chen H, et al (2012). [The relevance between the promoter hypermethylation of tshr and p16 gene and clinicopathological parameters in human papillary thyroid carcinoma]. J Capital Medical University, 33, 361-5
  6. Dai YL, Zhang F, Ye J, et al (2010). [P16 promoter hypermethylation in human papillary thyroid carcinoma]. Guangdong Medical Journal, 31, 1804-7.
  7. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  8. Elisei R, Shiohara M, Koeffler HP, et al (1998). Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer, 83, 2185-93. https://doi.org/10.1002/(SICI)1097-0142(19981115)83:10<2185::AID-CNCR18>3.0.CO;2-4
  9. Esteller M (2008). Epigenetics in cancer. N Engl J Med, 358, 1148-59. https://doi.org/10.1056/NEJMra072067
  10. Goyal N, Setabutr D, Abdulghani J, et al (2013). Molecular and genetic markers of follicular-cell thyroid cancer: etiology and diagnostic and therapeutic opportunities. Adv Exp Med Biol, 779, 309-26. https://doi.org/10.1007/978-1-4614-6176-0_14
  11. Hesson LB, Cooper WN, Latif F (2007). The role of RASSF1A methylation in cancer. Dis Markers, 23, 73-87. https://doi.org/10.1155/2007/291538
  12. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  13. Hoque MO, Rosenbaum E, Westra WH, et al (2005). Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab, 90, 4011-8. https://doi.org/10.1210/jc.2005-0313
  14. Huang P, Li DX, Zhang Y (2006). [Methylation of p16 gene and expression of p16 protein in human thyroid neoplasms]. J Practical Oncology, 21, 49-52
  15. Lam AK, Lo CY, Leung P, et al (2007). Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma. Ann Surg Oncol, 14, 1772-9. https://doi.org/10.1245/s10434-006-9280-9
  16. Li JJ, He Y (2008). [Expression and Alterations of p16 Gene in Human Primary Thyroid Neoplasm]. Progress in Modern Biomedicine, 8, 1253-5.
  17. Li XF, Jin YL, He ZL, et al (2013). [Detecting the abnormal methylation of plasma p16 promoter in patients with thyroid carcinoma by nested-methylation-specific polymerase chain reaction]. Chinese Journal of Prevention and Control of Chronic Diseases, 21, 34-6.
  18. M. Egger GDS, M. Schneider, and C. Minder (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ Open.
  19. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  20. Mazzaferri EL (2012). Managing thyroid microcarcinomas. Yonsei Med J, 53, 1-14. https://doi.org/10.3349/ymj.2012.53.1.1
  21. Mohammadi-asl J, Larijani B, Khorgami Z, et al (2011). Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARbeta2 genes in papillary thyroid carcinoma. Med Oncol, 28, 1123-8. https://doi.org/10.1007/s12032-010-9587-z
  22. Nasr MR, Mukhopadhyay S, Zhang S, et al (2006). Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. Mod Pathol, 19, 1631-7. https://doi.org/10.1038/modpathol.3800705
  23. Ojima H, Saito K, Yamauchi H, et al (2006). P16 protein abnormality in Epstein-Barr virus-associated gastric carcinomas. Anticancer Res, 26, 933-7.
  24. Peng ZL, Cao RX, Wen GB, et al (2006). [The methylation of p16 gene in papillary thyroid carcinoma]. J Modern oncology, 14, 1501-3
  25. Rayess H, Wang MB, Srivatsan ES (2012). Cellular senescence and tumor suppressor gene p16. Int J Cancer, 130, 1715-25. https://doi.org/10.1002/ijc.27316
  26. Schagdarsurengin U, Gimm O, Dralle H, et al (2006). CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid, 16, 633-42. https://doi.org/10.1089/thy.2006.16.633
  27. Schagdarsurengin U, Gimm O, Hoang-Vu C, et al (2002). Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res, 62, 3698-701.
  28. Sherman SI (2003). Thyroid carcinoma. Lancet, 361, 501-11. https://doi.org/10.1016/S0140-6736(03)12488-9
  29. Wang P, Pei R, Lu Z, et al (2013). Methylation of p16 CpG islands correlated with metastasis and aggressiveness in papillary thyroid carcinoma. J Chin Med Assoc, 76, 135-9. https://doi.org/10.1016/j.jcma.2012.11.007
  30. Wartofsky L (2010). Increasing world incidence of thyroid cancer: increased detection or higher radiation exposure? Hormones (Athens), 9, 103-8. https://doi.org/10.14310/horm.2002.1260
  31. Wiseman SM, Melck A, Masoudi H, et al (2008). Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol, 15, 2811-26. https://doi.org/10.1245/s10434-008-0034-8
  32. Xing M (2013). Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer, 13, 184-99. https://doi.org/10.1038/nrc3431
  33. Yang D, Zhang H, Hu X, et al (2012). Abnormality of pl6/ p38MAPK/p53/Wipl pathway in papillary thyroid cancer. Gland Surg, 1, 33-8.
  34. Yen TW, Shapiro SE, Gagel RF, et al (2003). Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery, 134, 890-9. https://doi.org/10.1016/S0039-6060(03)00408-2

Cited by

  1. STAT3 methylation in white blood cells as a novel sensitive biomarker for the toxic effect of low-dose benzene exposure vol.5, pp.3, 2016, https://doi.org/10.1039/C5TX00445D